Comments are due tonight in the USTR’s Section 301 investigation of German pharmaceutical pricing, a case that could put tariffs behind Washington’s demand that wealthy allies pay more for American medicines
WASHINGTON, Aug. 10, 2026
The public comment period in one of the most closely watched trade investigations of the year closes tonight at 11:59 p.m., as drug companies, patient groups, German industry and trade lawyers race to file submissions in the Office of the United States Trade Representative’s Section 301 investigation into what it calls Germany’s persistent underpayment for innovative pharmaceutical products. Today is also the deadline for parties to request an appearance at the public hearing scheduled for September 22 at the United States International Trade Commission in Washington, setting up an autumn showdown over whether the United States will, for the first time, use tariff law to attack an allied country’s domestic drug pricing system.
The investigation, initiated on June 18 and formally announced in a Federal Register notice published June 24, marks a sharp escalation in a campaign the administration has waged since last year to force wealthy countries to pay more for American-developed medicines. The USTR alleges that Germany, Europe’s largest pharmaceutical market, systematically underpays for innovative drugs through its statutory pricing framework, and that the result is a transfer of the global research and development burden onto American patients and insurers, who pay the world’s highest prices.
What the USTR Is Investigating
The Federal Register notice identifies two German policies at the center of the case. The first is a 9 percent price discount tied to pricing confidentiality: under recent changes to Germany’s drug pricing law, manufacturers that want to keep their negotiated reimbursement prices confidential must accept an additional 9 percent discount on those prices. The second is draft 2026 legislation that would layer a new mandatory rebate on patented medicines beginning in 2027. Industry analyses cited in coverage of the investigation, including reporting by Fierce Pharma and analysis by the law firm Troutman Pepper Locke, estimate that the proposed rebates could reach as high as 20 percent by 2030 when combined with existing discounts.
Germany’s pricing system, built around the AMNOG framework adopted in 2011, allows a new medicine to launch at a free price for a limited period while its added benefit is assessed, after which the manufacturer and the national association of statutory health insurers negotiate a reimbursement price. The system has long irritated the pharmaceutical industry, which argues that benefit assessments are stingy and that negotiated prices ripple far beyond Germany because dozens of other countries reference German prices when setting their own. That reference pricing effect is central to the USTR’s theory of harm: a discount extracted in Berlin echoes through Europe, Asia and Latin America, compounding what Washington sees as global free-riding on American innovation spending.
Section 301 of the Trade Act of 1974 authorizes the USTR to investigate and act against foreign acts, policies and practices that are unreasonable or discriminatory and that burden or restrict United States commerce. If the agency makes an affirmative determination, the statute permits remedies ranging from tariffs on German goods to withdrawal of trade concessions or a negotiated settlement in which Germany changes its pricing rules. The investigation has a statutory clock of 12 months, putting a decision on or before June 2027, though this administration has repeatedly moved faster than its deadlines.
An Investigation With Teeth Behind It
What gives the Germany case its unusual weight is the tariff architecture the administration has already built around pharmaceuticals. In April, President Trump signed a Section 232 proclamation imposing a 100 percent tariff on imported patented pharmaceutical products and their active ingredients, which took effect for large companies on July 31 and extends to smaller manufacturers on September 29. Generic drugs, biosimilars and certain specialty products including orphan drugs are exempt.
The proclamation created a lattice of carve-outs that function as leverage. Imports from the European Union, along with Japan, Korea, Switzerland, Liechtenstein and the United Kingdom, currently face a reduced 15 percent rate under recent framework agreements. Companies that sign most-favored-nation pricing agreements with the Department of Health and Human Services, committing to give American payers the lowest price they offer any developed country, and onshoring agreements with the Commerce Department can import at a zero tariff through January 2029. Firms that commit only to onshoring face a 20 percent rate.
The Section 301 case adds a country-specific instrument to that toolkit. Trade lawyers note that if the USTR finds Germany’s practices actionable, it could impose tariffs calibrated to German exports specifically, from automobiles to machinery to chemicals, rather than relying on the pharmaceutical tariffs alone. That prospect has already registered in Berlin and Brussels, where officials view the case as a template that could be replicated against other European health systems. The USTR has said openly that pharmaceutical pricing practices are among the issues it intends to pursue across multiple trading partners in its rebuilt Section 301 program, alongside digital services taxes, industrial overcapacity and forced labor.
Industry Cheers, Berlin Bristles
The American pharmaceutical industry has embraced the investigation. Stephen J. Ubl, president and chief executive of PhRMA, the industry’s main trade association, said the group appreciated the administration’s commitment to challenging unfair practices abroad and supported using Section 301 to achieve this goal. In its public statements, PhRMA has argued that foreign governments have systematically undervalued innovative medicines and named Germany, Japan, France and Canada among the high-income countries that should, in its words, pay their fair share of the cost of developing new therapies.
The industry’s argument rests on a striking asymmetry. The United States accounts for a large majority of global pharmaceutical profits despite representing a much smaller share of global volume, and American net prices for branded medicines run well above those in comparable economies. Manufacturers say that gap funds the research pipeline for everyone, and that European pricing systems set prices administratively at levels that would not sustain innovation if applied worldwide. Critics of the industry counter that the same companies choose to launch in Germany at negotiated prices because those prices remain profitable, and that the real driver of American prices is the structure of the United States market itself, including intermediaries and patent strategies that have nothing to do with Berlin.
The German government has not formally responded to the investigation in the USTR docket, but German officials and the European Commission have consistently rejected the premise that national health pricing is a trade barrier. Health policy is a jealously guarded national competence in Europe, and the draft German legislation at issue emerged from a domestic fiscal crunch: Germany’s statutory health insurance system has been running deficits, and successive governments have reached for pharmaceutical rebates as a budget valve. Forcing Germany to abandon planned savings would, in Berlin’s view, amount to Washington dictating German fiscal policy to benefit an industry that already earns healthy margins in Europe.
European pharmaceutical companies are caught in the middle. German and other European manufacturers export heavily to the United States and are simultaneously exposed to the Section 232 tariffs, the potential Section 301 remedies and any German pricing changes. Their trade association in Brussels has quietly encouraged a negotiated outcome, and several large European firms have already announced expanded American manufacturing investments, hedging against a world in which tariff walls around the United States pharmaceutical market become permanent.
From Executive Order to Trade Case
The road to today’s deadline runs through a pricing campaign that began well before the investigation was filed. In May 2025, President Trump signed an executive order directing agencies to pursue most-favored-nation pricing for prescription drugs, the principle that Americans should pay no more than the lowest price a manufacturer offers in any comparable developed country. The administration followed with letters to major pharmaceutical chief executives demanding voluntary price commitments, and through late 2025 and into this year it converted that pressure into signed agreements with a growing list of manufacturers, pairing American price concessions with tariff relief and, in several cases, commitments to raise prices abroad.
The logic of those deals created the need for a foreign enforcement arm. A company that promises Washington its best developed-world price has a powerful incentive to make sure no European government forces that reference price lower. When Germany’s statutory health insurers, facing a multibillion euro deficit, advanced legislation to expand mandatory rebates on patented medicines, the industry saw its most-favored-nation floor threatened at the source, and the administration saw an ally, in its telling, deepening the very underpayment problem the president had ordered fixed. The Section 301 filing followed within months of the German draft law becoming public.
Trade veterans note the historical echo. The United States used Section 301 aggressively in the 1980s against Japanese industrial policy and European agricultural practices, and pharmaceutical pricing disputes featured in trade negotiations with Korea, Australia and Canada across several administrations. What is new is the willingness to treat an ally’s core social insurance mechanism as an actionable trade practice on its own, without a trade agreement violation attached. The Germany case is the first Section 301 investigation ever aimed primarily at a developed country’s drug reimbursement system, and its outcome will define whether health budgets across the OECD become standing targets of American trade law.
Inside the Rebuilt Section 301 Machine
The Germany case is one gear in a much larger machine. After the Supreme Court struck down the administration’s emergency-powers tariffs in February, the USTR announced a program of Section 301 investigations designed to rebuild the tariff structure on more durable legal ground. On March 11, the agency opened investigations into structural excess capacity across 16 economies including China, the European Union, Japan, Korea, India and Mexico, covering sectors from steel and chemicals to semiconductors and ships. In June, it proposed and then finalized forced-labor tariffs of 10 to 12.5 percent on 60 trading partners, which took effect July 24 and now cover the overwhelming majority of United States imports. Agency officials have said publicly that pharmaceutical pricing, digital services taxes, discrimination against American technology companies and seafood practices are all on the docket for the same treatment.
That context shapes how Berlin reads the case. A finding against Germany would not arrive in isolation; it would land on top of the forced-labor tariff already applied to European goods, the excess-capacity investigation in which the EU is a named respondent, and the Section 232 regimes covering European cars, metals and medicines. European officials have described the accumulation as a strategy of layered leverage, in which each individual measure is small enough to discourage retaliation but the total burden steadily grows. The European Commission has so far responded with restraint, delaying countermeasures while pursuing negotiated arrangements, but officials in Brussels have warned that a tariff action premised on German health policy would test that patience in a way commodity disputes have not.
The procedural mechanics also matter for handicapping the outcome. Section 301 requires the USTR to request consultations with the foreign government concerned, and the agency has done so with Berlin. If consultations fail and the agency makes an affirmative determination, remedies must generally be implemented within 30 days of the determination, though the statute allows extensions. Because this is a discretionary investigation under Section 301(b), the ultimate decision on both the finding and the remedy rests with the trade representative acting under the president’s direction, which in practice means the White House can calibrate the outcome to the state of broader negotiations with Germany and the EU at decision time.
Tonight’s Deadline and What Comes Next
Under the schedule set out in the Federal Register notice, written comments and requests to appear at the hearing, along with a summary of expected testimony, must be filed through the USTR comments portal by 11:59 p.m. Eastern time tonight to be assured of consideration. The Section 301 Committee will convene its public hearing on September 22 at 10:00 a.m. in the main hearing room of the International Trade Commission at 500 E Street SW in Washington, with post-hearing rebuttal comments due seven calendar days after the hearing concludes.
The docket is expected to draw a familiar cast: PhRMA and the Biotechnology Innovation Organization supporting action, individual manufacturers filing detailed pricing narratives, German and European industry associations urging restraint, and health policy groups on both sides of the Atlantic warning about patient access. Trade bar veterans will also be watching for submissions from American employers and insurers, who have occasionally broken with the pharmaceutical industry by arguing that the goal should be lowering American prices rather than raising European ones.
The USTR faces genuine analytical questions. Quantifying the burden on United States commerce from another country’s reimbursement discount requires assumptions about how much of any German price increase would flow back into American research budgets rather than shareholder returns. The agency must also weigh the risk that tariff remedies against Germany would invite European counteraction at a moment when the administration is managing simultaneous disputes with Brazil at the World Trade Organization, an August 19 tariff escalation against Canada, and a fragile truce with China that runs through November 10.
What the Filings Will Argue
Submissions filed ahead of tonight’s deadline are expected to cluster around four arguments. Manufacturers and their associations will document the reference-pricing spillover, showing how German negotiated prices propagate through external reference pricing systems in dozens of countries and quantifying the alleged global revenue loss attributable to German discounts. They will argue that the 9 percent confidentiality discount is effectively a tax on the industry’s ability to prevent that propagation, since the only way to keep a German price from being referenced abroad is to pay Germany for the privilege of secrecy.
Opponents will attack the causal chain. Health economists filing on the other side are expected to argue that pharmaceutical research budgets are set by expected global returns in which Germany is one input among many, that the industry’s own capital allocation, including record buybacks and dividends, undercuts the claim that marginal German revenue would flow to laboratories, and that the United States cannot coherently demand both lower prices at home through most-favored-nation policies and higher prices abroad to fund innovation. German industry filings are likely to emphasize that American companies voluntarily participate in the German market on a scale that belies the underpayment narrative, and that Germany remains among the fastest countries in Europe to give patients access to new medicines, a direct consequence of the free-pricing launch window the AMNOG system provides.
A third group of filings will focus on remedies rather than liability, urging the USTR, if it finds against Germany, to pursue a negotiated settlement rather than tariffs, on the ground that duties on German goods would harm American importers and consumers without moving German health policy. And a fourth group, likely including some American payers and employer coalitions, will question the premise of the entire exercise, arguing that the path to sustainable American drug prices runs through domestic reform rather than trade coercion aimed at raising prices for allied countries’ patients.
Implications for Importers and the Health Sector
For companies that move pharmaceutical products across the Atlantic, the practical stakes compound an already complex year. Importers of patented drugs are living with the 100 percent Section 232 tariff or negotiating their way into the reduced-rate lanes, and customs teams are working through classification questions that the pharmaceutical tariffs created, including the treatment of active ingredients, combination products and goods in transit. A Section 301 action against Germany could add product-specific duties on an overlapping but distinct set of goods, and nothing in the statute requires the two regimes to be reconciled neatly.
Wholesalers and hospital systems, meanwhile, are watching inventory. The July 31 effective date for the Section 232 pharmaceutical tariff already prompted well-documented stockpiling in the second quarter, when pharmaceutical imports surged as manufacturers raced shipments ahead of the deadline. A German-specific action would likely trigger the same behavior on a narrower front. Supply chain managers who lived through the pandemic-era shortages warn that trade-driven inventory whipsaws in medicines carry patient-safety consequences that do not attach to solar panels or steel.
For the health policy world, the deeper question is whether trade law is becoming the enforcement arm of American drug pricing policy. The administration’s most-favored-nation push, its Section 232 tariffs and now the Section 301 case all point the same direction: Washington intends to compress the gap between American and foreign prices, and it would prefer that the compression happen by foreign prices rising. Germany is the test case because it is the largest European market and because its planned 2027 rebate gave the USTR a concrete, forward-looking measure to attack. If the strategy works in Berlin, France, Japan and Canada are unlikely to be far behind, a prospect PhRMA has openly encouraged.
Whether it works at all may depend on politics that no comment letter can reach. Germany’s governing coalition faces its own budget arithmetic, and trading away pharmaceutical savings would require offsetting cuts elsewhere in a strained health budget. American patients, for their part, will not see prices fall simply because German prices rise; any benefit runs through research incentives that pay off, if ever, over decades. What tonight’s deadline guarantees is that both sides of that argument will be on the record by morning, and that the September 22 hearing will give Washington’s newest trade weapon its first public test against an ally’s health system.